Skip to content Skip to footer
Subscribe Now
Insights+ Key Biosimilars Events of June 2021
INSIGHTS+
Insights+ Key Biosimilars Events of June 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of Jun, Celltrion launched Remsima SC (biosimilar, infliximab) for…
June 30, 20210Comments
Viewpoints_Nathalie Landry
VIEWPOINTS
PharmaShots Interview: Medicago’s Nathalie Landry Shares Insights on the Phase 2 Results of Plant-Based COVID-19 Vaccine
In an Interview with PharmaShots, Nathalie Landry, Executive Vice President, Scientific, and Medical Affairs at Medicago share her views on the P-II results of adjuvanted plant-based COVID-19 vaccine. Shots: The P-II study involves assessing the safety & immunogenicity of the CoVLP vs PBO in 306 subjects aged =18yrs. with two age groups (18-64yrs & over 65yrs.) across…
June 29, 20210Comments
Viewpoints_Kevin Cammack
VIEWPOINTS
PharmaShots Interview: Eli Lilly’s Kevin Cammack Shares Insights on Lilly’s Collaboration with Global Diabetes Technology Companies
In an interview with PharmaShots, Kevin Cammack, Head of Connected Care, Eli Lilly and Company shares insights on the Lilly alliance with DexCom, Glooko, myDiabby Healthcare, and Roche to provide compatibility between their unique digital management platforms and Lilly's Tempo Pen and Tempo Smart Button. Shots: Eli Lilly collaborates with DexCom, Glooko, myDiabby Healthcare, and Roche to…
June 28, 20210Comments
Thoughtspot_Sunaina Anand
THOUGHTSPOT
Nutraceuticals Under Evaluation for COVID-19 Prevention and Treatment
The pandemic has led to the identification of some promising nutraceuticals for the management and prevention of Covid-19. Nutraceuticals with their immune-boosting potential can amplify the body's defense system against the virus. For the past numerous decades, the medicinal action of natural compounds has gained focus as an alternate or adjuvant therapy approach in treating…
June 24, 20210Comments
Viewpoints_Dr. Bina Naik and Dr. Ashish Indani
VIEWPOINTS
PharmaShots Interview: Impact of new regulations and trends in the medical device industry in India – interviews of Dr. Bina Naik and Dr. Ashish Indani during DIA Medical Device Conference 20
The Medical Devices Conference was hosted by DIA India on 21st and 22nd February in collaboration with the Medical Technology Association of India (MTaI), AIC-AMTZ Medivalley Incubation Council and mDI Europa, is one of the largest gatherings of medical devices professionals in the region. The conference was focused on giving better insights into the challenges…
June 22, 20210Comments
Viewpoints_Thomas Slavin
VIEWPOINTS
PharmaShots Interview: Myriad Genetics’ Thomas Slavin Shares Insights on the Data Validating Breast Cancer PRS Across Ancestries
In an interview with PharmaShots, Dr. Thomas Slavin, M.D, Senior Vice President of Medical Affairs, Oncology at Myriad Genetics and study co-author shared his views on the data presented at ASCO 2021 and its implications for women. Shots: Myriad Genetics data helps more women to control their health by helping them understand their lifetime risk of developing…
June 22, 20210Comments
Viewpoints_Dr. Bob Deans
VIEWPOINTS
PharmaShots Interview: Synthego’s Dr. Bob Deans Shares Insights on the Launch of its Eclipse Platform for Drug Discovery
In an interview with PharmaShots, Dr. Bob Deans, Chief Scientific Officer at Synthego shares insights on the wide availability of its new CRISPR-based platform, Eclipse. Synthego created the Eclipse platform to enhance disease modeling, drug target identification, and validation, and accelerate cell therapy manufacturing. Shots: Eclipse uses MLto apply experience from several hundred thousand genome edits across…
June 22, 20210Comments
Viewpoints_Nan Li
VIEWPOINTS
PharmaShots Interview: Janssen’s Nan Li Shares Insights on the Data Presented at ISPOR 2021
In an interview with PharmaShots, Nan Li, Director of Access, Janssen Retina DAS shared her views on the attempts to quantify the economic burden of X-linked retinitis pigmentosa and achromatopsia. Shots: Janssen presented two posters on the economic burden and impact on people living with inherited retinal diseases X-linked retinitis pigmentosa (XLRP) and achromatopsia at ISPOR 2021…
June 21, 20210Comments

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]